Study: 50% hike in rep-hostile docs

Getting face time with busy physicians is becoming harder for pharma reps every year. The fraction of doctors open to meet reps fell nearly 20% last year—to 58% from 71%—while inaccessible doctors now account for 9% of the total, up from 6% last year—a 50% increase.

The findings come from ZS Associates' AccessMonitor report, which monitors rep-related interactions of more than 500,000 physicians, NPs and other prescribers nationwide and tracks both the planned and completed details of about half the nation's sales reps (more than 41,000).

Even docs who were open to seeing some reps became more selective. That trend made some 8 million planned sales calls nearly impossible to complete. Companies are requiring reps to call on prescribers who either refuse to see any sales people at all or refuse to see reps as often as management wants them to, and it's costing pharma more than $1 billion per year.
You must be a registered member of MMM to post a comment.
close

Next Article in Features


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.

Email Newsletters


Pharma continues to struggle with its image. Exhibit A is the public debate around the price of, and access to, new and innovative meds. As countless transformative technologies hit market, has industry done enough to anchor its permission to innovate? To provide a closer look at trends affecting trust over the past year, MM&M presents this e-book, "The 2015 Edelman Trust Barometer." Click here.